by Clinical Neuropsychologist | Thursday, October 24, 2024 | Dementia
Abstract INTRODUCTION Emerging preclinical evidence suggests that semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) for type 2 diabetes mellitus (T2DM) and obesity, protects against neurodegeneration and neuroinflammation. However, real-world evidence...
by Clinical Neuropsychologist | Thursday, October 24, 2024 | Dementia
Abstract INTRODUCTION This study evaluated the associations between Life’s Essential 8 (LE8) and cognitive performance, and compared the strength of the relationships of Life’s Simple 7 (LS7) and LE8 to cognition in midlife and older adults. METHODS...
by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) features changes in mitochondrial structure and function. Investigators debate where to position mitochondrial pathology within the chronology and context of other AD features. METHODS To address whether...
by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract INTRODUCTION The genetic pathways that influence longitudinal heterogeneous changes in Alzheimer’s disease (AD) may provide insight into disease mechanisms and potential therapeutic targets. METHODS Longitudinal endophenotypes from the Alzheimer’s...
by Clinical Neuropsychologist | Wednesday, October 23, 2024 | Dementia
Abstract INTRODUCTION The Alzheimer’s Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core was launched to advance Alzheimer’s disease (AD) and AD-related dementia (ADRD) health equity research in underrepresented populations (URPs). We describe our...
